Cure Parkinson’s and Alzheimer’s Research UK announce a partnership
Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach. We are recognising the overlap in underlying biological...
Learn more
Parkinson’s and dementia: improving cognitive measures to enable better treatments
Recently, several international Parkinson’s and Dementia with Lewy Bodies (DLB) advocacy organizations, including Cure Parkinson’s, held a roundtable to discuss the development of better tools for measuring cognitive changes in people with Parkinson’s and DLB.
Our two newest pre-clinical research projects
Cure Parkinson’s is pleased to announce the funding for two new projects as part of our annual iLCT Pipeline Research Acceleration Grant Programme.
STEM-PD, a cell-replacement trial for Parkinson’s, releases latest update
The STEM-PD trial has recently released an update, which indicates the team is proceeding to the next trial stage based on early positive safety data.
Clinical trial of lithium in Parkinson’s set to begin
We are delighted to announce funding for an upcoming phase1b clinical trial to investigate whether lithium, a drug currently used to treat mood disorders, could be repurposed to slow down Parkinson’s.
Accelerating Parkinson’s drug development: The International Linked Clinical Trials initiative
In 2012, Cure Parkinson’s joined forces with Van Andel Institute (VAI) to hold the first international Linked Clinical Trials (iLCT) meeting in Grand Rapids, Michigan. The Committee has since met annually to evaluate and prioritise drugs for clinical trial in Parkinson’s, a review of which has now been published in the Journal of Parkinson’s Disease.